Literature DB >> 18306990

Analysis of 6381 hepatocellular carcinoma patients in southern Taiwan: prognostic features, treatment outcome, and survival.

Chi-Sin Changchien1, Chao-Long Chen, Yi-Hao Yen, Jing-Houng Wang, Tsung-Hui Hu, Chuan-Mo Lee, Chih-Chi Wang, Yu-Fan Cheng, Yu-Jie Huang, Chih-Yun Lin, Sheng-Nan Lu.   

Abstract

BACKGROUND: This hospital-based analysis was conducted to identify prognostic factors of hepatocellular carcinoma (HCC) in a hepatitis B virus endemic area.
METHODS: A total of 6381 HCC cases, diagnosed from 1986 to 2002, were enrolled, and 2890 (42.3%) of them were not treated. Survival rates were analyzed by correlation with the national mortality databank. Missing data and correlations among prognostic factors were considered in the analysis.
RESULTS: The overall 1-year, 3-year, 5-year, and 7-year survival rates were 44.3%, 24.9%, 17.1%, and 13%, respectively. Multivariate analysis revealed that the independent factors influencing survival were the initial treatment modality, degree of liver function impairment, hepatitis B surface antigen positivity, tumor status, and alpha-fetoprotein. Besides these well-known prognostic factors, high alanine aminotransferase (ALT) levels and a high aspartate aminotransferase (AST)/ALT ratio were identified as independent poor prognostic factors.
CONCLUSIONS: This study, which considered untreated cases, missing data, and correlations between variables and official survival data sets, provides a large-scale comprehensive survival analysis. According to our results, high ALT and high AST/ALT were independent poor prognostic factors. Therefore, viral activity should be controlled in HCC patients, and patients with elevated AST/ALT ratios should be carefully monitored.

Entities:  

Mesh:

Year:  2008        PMID: 18306990     DOI: 10.1007/s00535-007-2134-9

Source DB:  PubMed          Journal:  J Gastroenterol        ISSN: 0944-1174            Impact factor:   7.527


  38 in total

1.  Effectiveness of interferon alfa on incidence of hepatocellular carcinoma and decompensation in cirrhosis type C. European Concerted Action on Viral Hepatitis (EUROHEP).

Authors:  G Fattovich; G Giustina; F Degos; G Diodati; F Tremolada; F Nevens; P Almasio; A Solinas; J T Brouwer; H Thomas; G Realdi; R Corrocher; S W Schalm
Journal:  J Hepatol       Date:  1997-07       Impact factor: 25.083

2.  Natural history of untreated nonsurgical hepatocellular carcinoma: rationale for the design and evaluation of therapeutic trials.

Authors:  J M Llovet; J Bustamante; A Castells; R Vilana; M del C Ayuso; M Sala; C Brú; J Rodés; J Bruix
Journal:  Hepatology       Date:  1999-01       Impact factor: 17.425

3.  Multivariate survival analysis using Cox's regression model.

Authors:  E Christensen
Journal:  Hepatology       Date:  1987 Nov-Dec       Impact factor: 17.425

4.  A new prognostic classification for predicting survival in patients with hepatocellular carcinoma. Groupe d'Etude et de Traitement du Carcinome Hépatocellulaire.

Authors:  S Chevret; J C Trinchet; D Mathieu; A A Rached; M Beaugrand; C Chastang
Journal:  J Hepatol       Date:  1999-07       Impact factor: 25.083

5.  Secular trends and geographic variations of hepatitis B virus and hepatitis C virus-associated hepatocellular carcinoma in Taiwan.

Authors:  Sheng-Nan Lu; Wei-Wen Su; Sheng-Shun Yang; Ting-Tsung Chang; Ken-Sheng Cheng; Jaw-Ching Wu; Hans Hsienhong Lin; Shun-Sheng Wu; Chuan-Mo Lee; Chi-Sin Changchien; Chien-Jen Chen; Jin-Chuan Sheu; Ding-Shinn Chen; Chien-Hung Chen
Journal:  Int J Cancer       Date:  2006-10-15       Impact factor: 7.396

6.  Prognostic factors for hepatocellular carcinoma presenting with macroscopic portal vein tumor thrombus.

Authors:  Haruhito Sakata; Masaru Konishi; Munemasa Ryu; Taira Kinoshita; Mitsuo Satake; Noriyuki Moriyama; Takenori Ochiai
Journal:  Hepatogastroenterology       Date:  2004 Nov-Dec

7.  Prognosis of hepatocellular carcinoma: the BCLC staging classification.

Authors:  J M Llovet; C Brú; J Bruix
Journal:  Semin Liver Dis       Date:  1999       Impact factor: 6.115

8.  High AST/ALT ratio may indicate advanced alcoholic liver disease rather than heavy drinking.

Authors:  H Nyblom; U Berggren; J Balldin; R Olsson
Journal:  Alcohol Alcohol       Date:  2004 Jul-Aug       Impact factor: 2.826

9.  Tumor invasiveness and prognosis in resected hepatocellular carcinoma. Clinical and pathogenetic implications.

Authors:  H C Hsu; T T Wu; M Z Wu; J C Sheu; C S Lee; D S Chen
Journal:  Cancer       Date:  1988-05-15       Impact factor: 6.860

10.  Diagnosis of hepatocellular carcinoma in patients with liver cirrhosis using liver function assays.

Authors:  T Itoshima; K Kawaguchi; M Ukida; T Ito; S Hattori; M Kitadai; H Ogawa; S Mizutani; K Kita; R Tanaka
Journal:  Acta Med Okayama       Date:  1984-04       Impact factor: 0.892

View more
  23 in total

1.  Platelet-related phenotypic patterns in hepatocellular carcinoma patients.

Authors:  Brian I Carr; Chih-Yun Lin; Sheng-Nan Lu
Journal:  Semin Oncol       Date:  2014-04-23       Impact factor: 4.929

2.  Prognostic impact of toll-like receptors 2 and 4 expression on monocytes in Egyptian patients with hepatocellular carcinoma.

Authors:  Asmaa M Zahran; Zeinab Albadry M Zahran; Omnia El-Badawy; Mona H Abdel-Rahim; Wageeh A M Ali; Amal Rayan; Muhammad Abbas El-Masry; Mohamed A A Abozaid; Helal F Hetta
Journal:  Immunol Res       Date:  2019-06       Impact factor: 2.829

3.  New macroscopic classification and back-flow thrombectomy for advanced hepatocellular carcinoma with portal vein tumor thrombus invading the contralateral second portal branch.

Authors:  Takumi Fukumoto; Masahiro Kido; Atsushi Takebe; Motofumi Tanaka; Hisoka Kinoshita; Kaori Kuramitsu; Shohei Komatsu; Daisuke Tsugawa; Tadahiro Goto; Sadaki Asari; Hirochika Toyama; Tetsuo Ajiki; Yonson Ku
Journal:  Surg Today       Date:  2017-03-21       Impact factor: 2.549

4.  Evaluation of seven different staging systems for alpha-fetoprotein expression in hepatocellular carcinoma after hepatectomy.

Authors:  Jianguo Zhou; Tao Yan; Xinyu Bi; Hong Zhao; Zhen Huang; Yefan Zhang; Yuan Li; Li Feng; Jing Wang; Jianqiang Cai
Journal:  Tumour Biol       Date:  2013-01-16

5.  Multidisciplinary Taiwan Consensus Recommendations for the Use of DEBDOX-TACE in Hepatocellular Carcinoma Treatment.

Authors:  Pi-Yi Chang; Chun-Chieh Huang; Chao-Hung Hung; Chih-Yung Yu; Ding-Kwo Wu; Jen-I Hwang; Po-Chin Liang; Reng-Hong Wu; Wei-Lun Tsai; Yih-Jyh Lin; Yi-Sheng Liu; Huei-Lung Liang; Rheun-Chuan Lee; Chien-Hung Chen
Journal:  Liver Cancer       Date:  2018-03-29       Impact factor: 11.740

Review 6.  The epidemiology of hepatocellular cancer: from the perspectives of public health problem to tumor biology.

Authors:  Stephen Caldwell; Sang H Park
Journal:  J Gastroenterol       Date:  2009-01-16       Impact factor: 7.527

7.  Validation of the 7th edition TNM staging system for hepatocellular carcinoma: an analysis of 8,828 patients in a single medical center.

Authors:  Kwong-Ming Kee; Jing-Houng Wang; Chih-Yun Lin; Chih-Chi Wang; Yu-Fan Cheng; Sheng-Nan Lu
Journal:  Dig Dis Sci       Date:  2013-05-24       Impact factor: 3.199

8.  Sorafenib after resection improves the outcome of BCLC stage C hepatocellular carcinoma.

Authors:  Jiang Li; Yu Hou; Xiao-Bei Cai; Bin Liu
Journal:  World J Gastroenterol       Date:  2016-04-21       Impact factor: 5.742

9.  Prospective screening increases the detection of potentially curable hepatocellular carcinoma: results in 8,900 high-risk patients.

Authors:  Francesco Izzo; Mauro Piccirillo; Vittorio Albino; Raffaele Palaia; Andrea Belli; Vincenza Granata; Sergio Setola; Roberta Fusco; Antonella Petrillo; Raffaele Orlando; Grazia Tosone; Fabrizio Scordino; Steven A Curley
Journal:  HPB (Oxford)       Date:  2013-04-22       Impact factor: 3.647

10.  Transcatheter arterial infusion chemotherapy with cisplatin-lipiodol suspension in patients with hepatocellular carcinoma.

Authors:  Masafumi Ikeda; Seishi Maeda; Hiroshi Ashihara; Hiroyasu Nagahama; Motohiko Tanaka; Yutaka Sasaki
Journal:  J Gastroenterol       Date:  2009-08-05       Impact factor: 7.527

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.